JP6010665B2 - Muscle bulking agent - Google Patents
Muscle bulking agent Download PDFInfo
- Publication number
- JP6010665B2 JP6010665B2 JP2015141552A JP2015141552A JP6010665B2 JP 6010665 B2 JP6010665 B2 JP 6010665B2 JP 2015141552 A JP2015141552 A JP 2015141552A JP 2015141552 A JP2015141552 A JP 2015141552A JP 6010665 B2 JP6010665 B2 JP 6010665B2
- Authority
- JP
- Japan
- Prior art keywords
- licorice
- muscle
- weight
- solvent
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003205 muscle Anatomy 0.000 title claims description 72
- 239000004067 bulking agent Substances 0.000 title claims description 27
- 241000202807 Glycyrrhiza Species 0.000 claims description 89
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 88
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 87
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 87
- 229940010454 licorice Drugs 0.000 claims description 87
- 239000000284 extract Substances 0.000 claims description 57
- 230000002209 hydrophobic effect Effects 0.000 claims description 42
- 239000003921 oil Substances 0.000 claims description 41
- 239000003960 organic solvent Substances 0.000 claims description 26
- 239000003125 aqueous solvent Substances 0.000 claims description 25
- 239000002904 solvent Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 16
- 230000001965 increasing effect Effects 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims 3
- 206010025482 malaise Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 70
- 235000019198 oils Nutrition 0.000 description 39
- 235000014113 dietary fatty acids Nutrition 0.000 description 34
- 239000000194 fatty acid Substances 0.000 description 34
- 229930195729 fatty acid Natural products 0.000 description 34
- 239000003925 fat Substances 0.000 description 32
- 235000019197 fats Nutrition 0.000 description 32
- 238000000605 extraction Methods 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- -1 fatty acid esters Chemical class 0.000 description 26
- 230000000694 effects Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 230000002354 daily effect Effects 0.000 description 15
- 150000004665 fatty acids Chemical class 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 150000005846 sugar alcohols Polymers 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 239000004378 Glycyrrhizin Substances 0.000 description 9
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 9
- 229960004949 glycyrrhizic acid Drugs 0.000 description 9
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 9
- 235000019410 glycyrrhizin Nutrition 0.000 description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 9
- 150000004667 medium chain fatty acids Chemical class 0.000 description 9
- 229940069445 licorice extract Drugs 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 125000005456 glyceride group Chemical group 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 210000000663 muscle cell Anatomy 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- ZZAIPFIGEGQNHP-AWEZNQCLSA-N 2-[(3r)-8,8-dimethyl-3,4-dihydro-2h-pyrano[2,3-f]chromen-3-yl]-5-methoxyphenol Chemical compound OC1=CC(OC)=CC=C1[C@H]1CC(C=CC2=C3C=CC(C)(C)O2)=C3OC1 ZZAIPFIGEGQNHP-AWEZNQCLSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- CUFAXDWQDQQKFF-DEOSSOPVSA-N Glabrol Chemical compound C1=C(O)C(CC=C(C)C)=CC([C@H]2OC3=C(CC=C(C)C)C(O)=CC=C3C(=O)C2)=C1 CUFAXDWQDQQKFF-DEOSSOPVSA-N 0.000 description 4
- CUFAXDWQDQQKFF-XMMPIXPASA-N Glabrol Natural products O=C1c2c(c(C/C=C(\C)/C)c(O)cc2)O[C@@H](c2cc(C/C=C(\C)/C)c(O)cc2)C1 CUFAXDWQDQQKFF-XMMPIXPASA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 230000002407 ATP formation Effects 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- NGGYSPUAKQMTNP-UHFFFAOYSA-N Glabrene Chemical compound C1=C(O)C=C2OCC(C3=C4OC(C=CC4=C(O)C=C3)(C)C)=CC2=C1 NGGYSPUAKQMTNP-UHFFFAOYSA-N 0.000 description 3
- KKLOCFOZPFGVBB-UHFFFAOYSA-N Glabrene Natural products C1=C(O)C=C2OCC(C3=CC=C4OC(C=CC4=C3O)(C)C)=CC2=C1 KKLOCFOZPFGVBB-UHFFFAOYSA-N 0.000 description 3
- 241001087269 Hispa Species 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000013310 margarine Nutrition 0.000 description 3
- 239000003264 margarine Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 238000005809 transesterification reaction Methods 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- ZZAIPFIGEGQNHP-UHFFFAOYSA-N (-/+)-3,4-Dihydro-3-(2-hydroxy-4-methoxyphenyl)-8,8-dimethyl-2H,8H-benzo<1,2-b:3,4-b'>dipyran, <rac-4'-O-Methylglabridin> Natural products OC1=CC(OC)=CC=C1C1CC(C=CC2=C3C=CC(C)(C)O2)=C3OC1 ZZAIPFIGEGQNHP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008268 mayonnaise Substances 0.000 description 2
- 235000010746 mayonnaise Nutrition 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 150000007951 prenylflavonoids Chemical group 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- PPBISUGOQDBBEL-UHFFFAOYSA-N 3'-Hydroxy-4'-O-methyl-glabridin Natural products OC1=C(O)C(OC)=CC=C1C1CC(C=CC2=C3C=CC(C)(C)O2)=C3OC1 PPBISUGOQDBBEL-UHFFFAOYSA-N 0.000 description 1
- PPBISUGOQDBBEL-ZDUSSCGKSA-N 3-[(3R)-8,8-dimethyl-3,4-dihydro-2H-pyrano[2,3-f]chromen-3-yl]-6-methoxybenzene-1,2-diol Chemical compound COc1ccc([C@@H]2COc3c(C2)ccc2OC(C)(C)C=Cc32)c(O)c1O PPBISUGOQDBBEL-ZDUSSCGKSA-N 0.000 description 1
- CNNBJLXLTIKXGJ-UHFFFAOYSA-N 3-phenyl-2h-chromene Chemical compound C1OC2=CC=CC=C2C=C1C1=CC=CC=C1 CNNBJLXLTIKXGJ-UHFFFAOYSA-N 0.000 description 1
- CJUFYKORDZSOLF-INIZCTEOSA-N 6-[(3r)-8,8-dimethyl-3,4-dihydro-2h-pyrano[2,3-f]chromen-3-yl]-2,2-dimethylchromen-5-ol Chemical compound O1C(C)(C)C=CC2=C1C=CC(C1)=C2OC[C@H]1C1=CC=C2OC(C)(C)C=CC2=C1O CJUFYKORDZSOLF-INIZCTEOSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000026709 Liddle syndrome Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 206010037113 Pseudoaldosteronism Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010043298 Testicular atrophy Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000010788 atrophy of testis Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- CJUFYKORDZSOLF-MRXNPFEDSA-N hispaglabridin B Natural products Oc1c([C@H]2COc3c4c(OC(C)(C)C=C4)ccc3C2)ccc2OC(C)(C)C=Cc12 CJUFYKORDZSOLF-MRXNPFEDSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- NNQSGBRGJHSRFN-UHFFFAOYSA-N isoflavan Chemical compound C1OC2=CC=CC=C2CC1C1=CC=CC=C1 NNQSGBRGJHSRFN-UHFFFAOYSA-N 0.000 description 1
- 235000002324 isoflavanes Nutrition 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 231100001044 testicular atrophy Toxicity 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
本発明は、医薬品やその他様々な用途に使用することができる、筋肉増量剤に関する。 The present invention relates to a muscle bulking agent that can be used for pharmaceuticals and various other uses.
一般に、筋肉の量を増加させるためには、筋肉に対してレジスタンス運動等の特別な運動による負荷をかけ、筋肉の破壊と修復を繰り返す必要のあることが知られている。また、運動負荷による筋肉の増量効果を高めることを目的として、種々のサプリメントが用いられている。
レジスタンス運動とは、筋肉にさまざまな負荷抵抗をかけて行うトレーニングの総称であり、筋力トレーニング、ウエイトトレーニングなどとも呼ばれているが、筋肉の増量のみならず、筋力や筋持久力などを向上させることを目的する場合も含まれること、負荷形態としてウエイトの他、弾性抵抗性、粘性抵抗性、電磁抵抗性など、さまざまなものが用いられるようになったことから、レジスタンス運動と総称されるようになった。その性格上、主要な目的は筋肉増強と肥大である（非特許文献１）。
筋肉増強剤としては、成長ホルモンの利用が検討されているが、成長ホルモンには、ドーピングの問題や高血圧、発がん性、肝臓障害、精巣萎縮、無月経、妄想、パラノイアなど心身的な副作用の問題があり、日々、長期的に継続摂取するのには好ましくないとされている。筋肉増強のための食事療法としては、筋肉の材料となるタンパク質、アミノ酸の摂取が奨励されているが、明確な効果は薄く、個人により大差のあるのが現実である。
In general, it is known that in order to increase the amount of muscle, it is necessary to apply a load by special exercise such as resistance exercise to the muscle, and to repeatedly destroy and repair the muscle. Moreover, various supplements are used for the purpose of enhancing the effect of increasing muscles due to exercise load.
Resistance exercise is a general term for training with various load resistance applied to muscles, and is also called strength training, weight training, etc., but it improves muscle strength and muscle endurance as well as muscle gain. In addition to weight, various types of load such as elastic resistance, viscous resistance, electromagnetic resistance, etc. have come to be used. Became. In its character, the main purpose is muscle strengthening and hypertrophy (Non-patent Document 1).
Growth hormone is being investigated as a muscle augmentation agent. However, growth hormone has problems such as doping problems and psychosomatic side effects such as hypertension, carcinogenicity, liver damage, testicular atrophy, amenorrhea, delusions, and paranoia. Therefore, it is said that it is not preferable for daily long-term continuous intake. As a diet for muscle strengthening, intake of protein and amino acids, which are muscle materials, is encouraged, but the clear effect is thin and the reality is that there is a great difference between individuals.
一方、甘草から得られる抽出物のうち、甘草フラボノイドを多く含み、グリチルリチン含量が極微量である甘草疎水性抽出物は、マルチプル・リスク・ファクター症候群の予防や処置に有用であることが見出されている（特許文献１）。さらに最近の研究において、この甘草疎水性抽出物がＰＰＡＲγリガンド活性を有することや、その活性成分がフラボノイドであることが見出されている（特許文献２）。 On the other hand, among the extracts obtained from licorice, a licorice hydrophobic extract containing a large amount of licorice flavonoids and having a very small amount of glycyrrhizin was found to be useful for the prevention and treatment of multiple risk factor syndrome. (Patent Document 1). Further, in recent studies, it has been found that this licorice hydrophobic extract has PPARγ ligand activity and that its active ingredient is a flavonoid (Patent Document 2).
また、甘草又は甘草抽出物を必須成分とする、筋肉活性化剤が報告されている（特許文献３）。ここでいう筋肉活性化剤とは、筋細胞におけるエネルギー産生、すなわちＡＴＰ産生量を促進し、筋収縮力を向上させることにより皮膚の萎縮やしわ、たるみ等の変化を抑制又は改善させるものである。さらに、特許文献３で示される筋肉活性化剤に、ビタミンＣ誘導体およびビタミンＥ誘導体を加えることにより、筋細胞におけるＡＴＰ産生が相乗的に促進されることが報告されている（特許文献４）。しかし、ＡＴＰは筋肉収縮のためのエネルギーであって、筋肉増量とは関係なく、ビタミンＣ誘導体およびビタミンＥ誘導体もＡＴＰ産生促進のために添加されていると考えられる。 Moreover, the muscle activator which uses a licorice or a licorice extract as an essential component has been reported (patent document 3). The muscle activator here is one that suppresses or improves changes in skin atrophy, wrinkles, sagging, etc. by promoting energy production in muscle cells, that is, ATP production, and improving muscle contraction. . Furthermore, it has been reported that ATP production in muscle cells is synergistically promoted by adding a vitamin C derivative and a vitamin E derivative to the muscle activator shown in Patent Document 3 (Patent Document 4). However, ATP is energy for muscle contraction, and it is considered that vitamin C derivatives and vitamin E derivatives are also added to promote ATP production regardless of muscle gain.
本発明の目的は、レジスタンス運動等の特別な運動による運動負荷を必ずしも必要とせず、摂取することで筋肉量を効果的に増加させることを可能とする筋肉増量剤を提供することである。 An object of the present invention is to provide a muscle bulking agent that does not necessarily require exercise load due to special exercise such as resistance exercise, and can increase muscle mass effectively by ingestion.
このような事情のもと、本発明者らが、鋭意研究を重ねた結果、甘草を含水率１５重量％以下の非水溶剤で抽出して得られる甘草疎水性抽出物に、日常的な運動量で、効果的に筋肉量の増量ができる効果があることを見出し、本発明を完成するに至った。
すなわち本発明は、甘草を含水率１５重量％以下の非水溶剤で抽出して得られる甘草疎水性抽出物を有効成分として含有する筋肉増量剤に関する。
Under such circumstances, the present inventors have conducted intensive research, and as a result, the licorice hydrophobic extract obtained by extracting licorice with a non-aqueous solvent having a water content of 15% by weight or less is used as a daily exercise amount. Thus, the inventors have found that there is an effect of effectively increasing muscle mass, and have completed the present invention.
That is, the present invention relates to a muscle bulking agent containing, as an active ingredient, a licorice hydrophobic extract obtained by extracting licorice with a nonaqueous solvent having a water content of 15% by weight or less.
本発明の筋肉増量剤は、特別な運動を行わなくとも優れた筋肉量の増加作用を示すことから、健康体における筋肉増量のためのサプリメントとしてだけでなく、筋萎縮抑制、又は寝たきり予防にも有効である。本発明の筋肉増量剤は、食経験が豊富で安全性の高いため、日常的に継続して摂取することができることから、医薬品としてだけでなく、様々な用途に利用できる。 Since the muscle bulking agent of the present invention exhibits an excellent muscle mass increasing action without performing special exercise, not only as a supplement for muscle weight gain in a healthy body, but also for muscle atrophy suppression or bedridden prevention. It is valid. Since the muscle bulking agent of the present invention has abundant dietary experience and high safety, it can be ingested on a daily basis, so that it can be used not only as a pharmaceutical product but also in various applications.
以下に、本発明の実施の形態を詳しく説明する。 Hereinafter, embodiments of the present invention will be described in detail.
本発明の筋肉増量剤は、甘草を含水率１５重量％以下の非水溶剤で抽出して得られる甘草疎水性抽出物を有効成分として含有する組成物である。本発明における「筋肉増量剤」とは、筋肉の量そのものを増加させる作用を有するものを意味し、筋細胞におけるエネルギー産生を促進することで筋肉を活性化する従来の筋肉増強剤とは異なる。本発明における筋肉増量のメカニズムとしては特に限定されず、筋肉細胞数の増加、筋肉細胞の肥大、あるいはそれらの組み合わせやその他の要因いずれであっても、筋肉自体の絶対量を増加させる全ての態様が包含される。 The muscle bulking agent of the present invention is a composition containing, as an active ingredient, a licorice hydrophobic extract obtained by extracting licorice with a nonaqueous solvent having a water content of 15% by weight or less. The “muscle-increasing agent” in the present invention means an agent that has an action of increasing the amount of muscle itself, and is different from a conventional muscle-enhancing agent that activates muscles by promoting energy production in muscle cells. The mechanism for increasing the muscle mass in the present invention is not particularly limited, and all aspects of increasing the absolute amount of the muscle itself regardless of the increase in the number of muscle cells, hypertrophy of the muscle cells, or combinations thereof or other factors. Is included.
本発明の筋肉増量剤の有効成分である甘草疎水性抽出物は、甘草より得ることができる。本発明の筋肉増量剤の原料として用いられる甘草材料は、マメ科カンゾウ属（Glycyrrhiza属）の植物であれば限定されず、グリキルリーザ・グラブラ（G. glabra）、グリキルリーザ・ウラレンシス（G. uralensis）、グリキルリーザ・インフラータ（G. inflata）などが挙げられる。中でも最も分布が広く食経験も豊かなグリキルリーザ・グラブラ種の甘草が好ましい。
本発明において、甘草疎水性抽出物を、甘草から得る場合の方法は特に限定されないが、例えば甘草またはその粉末を、非水溶剤と接触させることで目的成分を抽出することによって得ることができる。あるいは、あらかじめ甘草中の親水性成分を水あるいはアルカリ水溶液を用いて抽出・除去した後、その甘草残渣または該甘草残渣を乾燥させたものを用いて、同様に、非水溶剤を接触させることでも抽出することもできる。
The licorice hydrophobic extract which is an active ingredient of the muscle bulking agent of the present invention can be obtained from licorice. The licorice material used as a raw material for the muscle bulking agent of the present invention is not limited as long as it is a plant of the genus Leguminosae (Glycyrrhiza genus). For example, Grykyrieza Inflata (G. inflata). Among them, glycyrrhiza grabra licorice with the widest distribution and rich food experience is preferred.
In the present invention, the method for obtaining the licorice hydrophobic extract from licorice is not particularly limited, but it can be obtained, for example, by extracting licorice or a powder thereof by bringing it into contact with a non-aqueous solvent. Alternatively, the hydrophilic component in licorice can be extracted and removed in advance using water or an alkaline aqueous solution, and then the licorice residue or the dried licorice residue can be used, and similarly, contacted with a non-aqueous solvent. It can also be extracted.
本発明において抽出溶媒として使用する非水溶剤としては、水以外の溶剤であれば特に限定されず、有機溶剤、油脂又はそれらの混合溶剤が好ましく使用できる。有機溶剤としては、特に制限されないが、医薬品や食品、食品添加物などの製造、加工に使用できる安全なものが好ましく、例えば、アセトン、メタノール、エタノール、プロパノール、ブタノールなどの炭素数１〜４の１価アルコール、グリセリン、プロピレングリコールなどの多価アルコール、脂肪酸エステル、ジエチルエーテルなどのエーテル、ヘキサン、ヘプタン、シクロヘキサンなどの炭化水素などが挙げられ、またこれらの溶剤のうち少なくとも２種以上を混合して用いても良い。これらのうち、好適に使用しうる溶剤としては、酢酸エチル等の脂肪酸エステルや、メタノール、エタノール、プロパノール、ブタノール、アセトン、ヘキサン、ヘプタン、ジエチルエーテル、シクロヘキサン、プロピレングリコール、グリセリン等である。その中でも、メタノール、エタノール、プロパノール、ブタノール、アセトン、プロピレングリコール、グリセリンなどの水溶性有機溶剤が好ましく、水溶性有機溶剤のなかでも、メタノール、エタノール、プロパノール、ブタノール、アセトンがより好ましく、とりわけエタノールが好ましい。油脂としては、特に制限されず、医薬品や食品、食品添加物などの製造、加工に使用できる安全なものが使用できるが、後述するように、多価アルコール脂肪酸エステルなどの多価アルコールの誘導体を含有するものが好ましく、多価アルコール脂肪酸エステルとして、中鎖脂肪酸トリグリセリドを含むグリセリン脂肪酸エステルや脂肪酸部分グリセリドを含むグリセリン脂肪酸エステルがより好ましい。そのような観点から、油脂として、中鎖脂肪酸トリグリセリドやジグリセリドやそれらの混合物を含むものが特に好ましい。
本発明においては、これら非水溶剤は、含水率が１５重量％以下のものを使用する必要がある。本発明における筋肉増量という効果を十分に発揮するためには、抽出に使用される非水溶剤の含水率としては低い方が好ましく、例えば１３重量％（約１０容量％）以下が好ましく、１０重量％（約８容量％）以下がより好ましく、８重量％以下がさらに好ましく、６重量％以下が特に好ましい。その下限は、特に制限されないが、エタノールなどの水溶性の有機溶剤を使用する場合は、実用性の観点から、普通１重量％以上、好ましくは３重量％以上である。もちろん、水を全く含まない、すなわち含水率０容量％の非水溶剤も好ましく使用できる。
In the present invention, the non-aqueous solvent used as the extraction solvent is not particularly limited as long as it is a solvent other than water, and an organic solvent, oil or a mixed solvent thereof can be preferably used. Although it does not restrict | limit especially as an organic solvent, The safe thing which can be used for manufacture and processing of a pharmaceutical, a foodstuff, a food additive, etc. is preferable, for example, C1-C4, such as acetone, methanol, ethanol, propanol, butanol Examples include monohydric alcohols, polyhydric alcohols such as glycerin and propylene glycol, fatty acid esters, ethers such as diethyl ether, hydrocarbons such as hexane, heptane, and cyclohexane, and a mixture of at least two of these solvents. May be used. Among these, solvents that can be suitably used include fatty acid esters such as ethyl acetate, methanol, ethanol, propanol, butanol, acetone, hexane, heptane, diethyl ether, cyclohexane, propylene glycol, glycerin, and the like. Among them, water-soluble organic solvents such as methanol, ethanol, propanol, butanol, acetone, propylene glycol, and glycerin are preferable, and among water-soluble organic solvents, methanol, ethanol, propanol, butanol, and acetone are more preferable, and ethanol is particularly preferable. preferable. The fats and oils are not particularly limited, and safe ones that can be used for the production and processing of pharmaceuticals, foods, food additives, etc. can be used. As described later, polyhydric alcohol derivatives such as polyhydric alcohol fatty acid esters are used. What is contained is preferable, and as the polyhydric alcohol fatty acid ester, a glycerin fatty acid ester containing a medium-chain fatty acid triglyceride or a glycerin fatty acid ester containing a fatty acid partial glyceride is more preferable. From such a viewpoint, those containing medium-chain fatty acid triglycerides, diglycerides, and mixtures thereof are particularly preferable as fats and oils.
In the present invention, these non-aqueous solvents need to have a water content of 15% by weight or less. In order to sufficiently exert the effect of increasing the muscle mass in the present invention, the water content of the non-aqueous solvent used for extraction is preferably low, for example, 13% by weight (about 10% by volume) or less is preferable, and 10% by weight. % (About 8% by volume) or less, more preferably 8% by weight or less, and particularly preferably 6% by weight or less. The lower limit is not particularly limited, but when a water-soluble organic solvent such as ethanol is used, it is usually 1% by weight or more, preferably 3% by weight or more from the viewpoint of practicality. Of course, a non-aqueous solvent containing no water, that is, having a water content of 0% by volume can also be preferably used.
甘草の非水溶剤による抽出は、一般的な方法に従って実施することができ、特に制限されない。抽出温度は、特に制限されず、系の固化温度から沸点の間、一般に−２０〜１００℃ 、普通１〜８０℃ 、好ましくは２０〜６０℃の範囲で好適に実施しうる。抽出の操作は、上記の甘草に対して、例えば１〜２０倍容量、好ましくは２〜１０倍容量の上記非水溶剤を用いて、例えば、０．１時間以上、好ましくは０ ．２時間以上、より好ましくは０．５時間以上、甘草と非水溶剤を接触させることで抽出を行えば良い。普通、１回当たりの抽出時間は１〜１０時間程度で好適に実施しうる。抽出時間の上限は特に制限されず、１日程度であるが、更に長時間行っても良い。抽出は、必要に応じて、１回もしくは複数回実施しても良く、また用いる溶剤を適宜組み合わせても良い。抽出時の圧力は、特に制限されない。常圧〜加圧された状態（１〜数気圧）が用いられうるが、所望ならば減圧にすることもできる。また還流下にやや加圧された状態でも実施しうる。
本発明の筋肉増量剤において、甘草疎水性抽出物は、上記のようにして得られる抽出物をそのまま使用してもよいが、さらに精製工程、たとえばカラム処理、脱臭処理、脱色処理などにより粗精製又は精製したものを使用してもよい。本発明の抽出方法によって得られる甘草疎水性抽出物には、甘草の疎水性成分である甘草ポリフェノールが多く含まれる。さらに、甘草ポリフェノールの多くは抗酸化作用を有し、また、その化合物の構造にプレニルフラボノイド基を有していることが特徴である。本発明の筋肉増量剤の有効成分である甘草疎水性抽出物に含まれるプレニルフラボノイド基を有する甘草ポリフェノールの含量は、その総量として通常約０．０１〜１００重量％であるが、０．１〜９９重量％含有しているものが好ましく、１〜８０重量％含有しているものがより好ましく、３〜５０重量％含有しているものがさらに好ましい。
Extraction of licorice with a non-aqueous solvent can be carried out according to a general method, and is not particularly limited. The extraction temperature is not particularly limited, and can be suitably carried out in the range from the solidification temperature to the boiling point of the system, generally from -20 to 100 ° C, usually from 1 to 80 ° C, preferably from 20 to 60 ° C. The extraction operation is performed, for example, for 0.1 hour or more, preferably 0. Extraction may be performed by bringing licorice and a nonaqueous solvent into contact with each other for 2 hours or longer, more preferably 0.5 hours or longer. Usually, the extraction time per time is preferably about 1 to 10 hours. The upper limit of the extraction time is not particularly limited and is about one day, but it may be performed for a longer time. The extraction may be performed once or a plurality of times as necessary, and the solvents to be used may be appropriately combined. The pressure at the time of extraction is not particularly limited. Normal pressure to pressurized state (1 to several atmospheres) can be used, but reduced pressure can be used if desired. It can also be carried out in a slightly pressurized state under reflux.
In the muscle bulking agent of the present invention, as the licorice hydrophobic extract, the extract obtained as described above may be used as it is, but further purified by a purification step such as column treatment, deodorization treatment, decolorization treatment, etc. Alternatively, a purified product may be used. The licorice hydrophobic extract obtained by the extraction method of the present invention contains a large amount of licorice polyphenol which is a hydrophobic component of licorice. Furthermore, many licorice polyphenols have an antioxidant action and are characterized by having a prenylflavonoid group in the structure of the compound. The content of the licorice polyphenol having a prenylflavonoid group contained in the licorice hydrophobic extract, which is an active ingredient of the muscle bulking agent of the present invention, is usually about 0.01 to 100% by weight as a total amount. Those containing 99% by weight are preferred, those containing 1 to 80% by weight are more preferred, and those containing 3 to 50% by weight are more preferred.
本発明の筋肉増量剤においては、上記甘草ポリフェノールとして、グラブレン、グラブリジン、グラブロール、３’−ヒドロキシ−４’−Ｏ−メチルグラブリジン、４’−Ｏ−メチルグラブリジン、ヒスパグラブリジンＢからなる群より選ばれた少なくとも１つの化合物を少なくとも含有しているのが好ましい。該化合物は、甘草、好ましくはＧ．グラブラ種の甘草を、エタノール、ヘキサン、アセトンなどの有機溶剤で抽出することによって得ることができ、該抽出物のまま使用してもよいが、さらにカラム処理、脱臭処理、脱色処理などにより粗精製又は精製したものを使用してもよい。勿論、該化合物は、その他植物等の天然由来のものや、化学合成あるいは培養細胞などにより生合成した化合物のいずれであっても使用することができる。また、該化合物は、精製したものを使用することができるが、飲食品、医薬品、医薬部外品などとして不適当な不純物を含有しない限り粗精製したものを使用することもできる。
該化合物の中でも、グラブリジンを含有し、かつグラブレン、グラブロール、３’−ヒドロキシ−４’−Ｏ−メチルグラブリジン、４’−Ｏ−メチルグラブリジン、ヒスパグラブリジンＢからなる群より選ばれた少なくとも１つの化合物を含有することが好ましい。さらに、グラブリジン及びグラブレンを含有し、かつグラブロール、３’−ヒドロキシ−４’−Ｏ−メチルグラブリジン、４’−Ｏ−メチルグラブリジン、ヒスパグラブリジンＢからなる群より選ばれた少なくとも１つの化合物を含有することがより好ましい。とりわけ、グラブレン、グラブリジン、グラブロール、３’−ヒドロキシ−４’−Ｏ−メチルグラブリジン、４’−Ｏ−メチルグラブリジン、ヒスパグラブリジンＢを全て含有していることが最も好ましい。
In the muscle bulking agent of the present invention, the licorice polyphenol is selected from the group consisting of glabrene, glabrizine, glabrol, 3'-hydroxy-4'-O-methyl glabridine, 4'-O-methyl glabrizine, and hispagrabridine B. It is preferable to contain at least one selected compound. The compound is a licorice, preferably G. Grubra seed licorice can be obtained by extraction with an organic solvent such as ethanol, hexane, acetone, etc., and the extract may be used as it is, but it is further purified by column treatment, deodorization treatment, decolorization treatment, etc. Alternatively, a purified product may be used. Of course, the compound may be any of those derived from other natural sources such as plants, and those that are chemically synthesized or biosynthesized by cultured cells. Moreover, although the refined | purified thing can be used for this compound, as long as it does not contain an unsuitable impurity as food / beverage products, a pharmaceutical, a quasi-drug, etc., it can also use the roughly refined | purified thing.
Among these compounds, at least one selected from the group consisting of grabridine and comprising grabrene, grabrol, 3′-hydroxy-4′-O-methyl grabridine, 4′-O-methyl grabridine, Hispa grabridine B It is preferable to contain a compound. Furthermore, it contains at least one compound selected from the group consisting of glabrizine and glabrene, and also consisting of glabrol, 3′-hydroxy-4′-O-methyl glabridine, 4′-O-methyl glabridine, and Hispa grab lysine B More preferably. In particular, it is most preferable to contain all of grabrene, grabridine, grabrol, 3′-hydroxy-4′-O-methyl grabridine, 4′-O-methyl grabridine, and hispagrabridine B.
ここで、グラブリジン（glabridin）、３’−ヒドロキシ−４’−Ｏ−メチルグラブリジン（3’-hydroxyl-4’-O-methylglabridin）、４’−Ｏ−メチルグラブリジン（4’-O-methylglabridin）、ヒスパグラブリジンＢ（hyspaglabridin B）はイソフラバン（isoflavan）に分類されるフラボノイドであり、下記一般式（1）にて表される化合物である。 Here, glabridin, 3′-hydroxy-4′-O-methylglabridin, 4′-O-methylglabridin, 4′-O-methylglabridin, Hispaglabridin B is a flavonoid classified into isoflavan, and is a compound represented by the following general formula (1).
〔グラブリジンはＲ１＝Ｈ、Ｒ２＝ＯＨ；３’−ヒドロキシ−４’−Ｏ−メチルグラブリジンはＲ１＝ＯＨ、Ｒ２＝ＯＣＨ３；４’−Ｏ−メチルグラブリジンはＲ１＝Ｈ、Ｒ２＝ＯＣＨ３；ヒスパグラブリジンＢはＲ１〜Ｒ２が−ＣＨ＝ＣＨ−Ｃ（ＣＨ３）２−Ｏ−で六員環を構成する。〕
グラブレン（glabrene）は、イソフラブ−３−エン（isoflav-3-ene）に分類されるフラボノイドであり、下記一般式（２）で表される化合物である。
[Gravidine is R1 = H, R2 = OH; 3′-hydroxy-4′-O-methylgrabridine is R1 = OH, R2 = OCH 3 ; 4′-O-methylgrabridine is R1 = H, R2 = OCH 3 ; In Hispagrabridine B, R1 to R2 are —CH═CH—C (CH 3 ) 2 —O— to form a six-membered ring. ]
Glabrene is a flavonoid classified into isoflav-3-ene and is a compound represented by the following general formula (2).
グラブロール（glabrol）は、フラバノン（flavanone）に分類されるフラボノイドであり、下記一般式（３）で表される化合物である。 Glabrol is a flavonoid classified as flavanone, and is a compound represented by the following general formula (3).
グラブレン、グラブリジン、グラブロール、３’−ヒドロキシ−４’−Ｏ−メチルグラブリジン、４’−Ｏ−メチルグラブリジン、ヒスパグラブリジンＢは、甘草の中でも主としてグリキリーザ・グラブラ（Glycyrrhiza glabra）に特異的に含まれる成分である。ただし、Ｇ．グラブラと他品種との雑種においては含まれる場合もある。該化合物は、ＯＤＳなどの逆相カラムを用いたＨＰＬＣ分析により、他のフラボノイド成分と分離して検出、定量することができる。 Gravuren, glabrizine, glabrol, 3′-hydroxy-4′-O-methyl glabrizine, 4′-O-methyl glabrizine, and hispagrabridine B are mainly contained in licorice mainly in Glycyrrhiza glabra. It is an ingredient. However, G. It may be included in hybrids of grabra and other varieties. The compound can be detected and quantified separately from other flavonoid components by HPLC analysis using a reverse phase column such as ODS.
本発明の筋肉増量剤においては、上記化合物を、油脂に溶解した状態で含有するのが好ましい。その場合、精製あるいは合成された上記化合物を直接油脂に溶解して本発明の筋肉増量剤の有効成分として使用してもかまわないが、後述するように、甘草を有機溶剤で抽出して、上記化合物を含有する甘草疎水性抽出物を得、該抽出物に油脂を接触混合する方法が簡便で好ましい。 In the muscle bulking agent of this invention, it is preferable to contain the said compound in the state melt | dissolved in fats and oils. In this case, the purified or synthesized compound may be directly dissolved in fats and oils and used as an active ingredient of the muscle bulking agent of the present invention. As described later, licorice is extracted with an organic solvent, A method of obtaining a licorice hydrophobic extract containing a compound and contacting the extract with fats and oils is simple and preferred.
ところで、本発明においては、甘草疎水性抽出物中の有効成分含量を高め、且つ、グリチルリチン等の水溶性不純物の含量を低く抑えることが重要である。グリチルリチンは医薬としても利用されているが、血圧上昇作用、心筋障害、水血症（ 以上、Harders, H. & Rausch-Stroomann, J. G., Munch. Med. Wschr. 95, 580 (1953) ) 、低カリウム血症、血漿レニン活性減少、偽性アルドステロン症、四肢弛緩性麻痺(以上、Conn, J. W., Rovner, D. R. & Cohen, E. L., J. Am. Med. Assoc. 205, 492( 1968) ) 、尿中アルドステロン排泄減少、浮腫、頭痛、嗜眠状態(以上、Epstein, M. T., et al., Brit. Med. J., 1, 488 (1977) )等の副作用があり、またショ糖の１５０倍の甘さがある。 By the way, in the present invention, it is important to increase the active ingredient content in the licorice hydrophobic extract and to keep the content of water-soluble impurities such as glycyrrhizin low. Glycyrrhizin is also used as a medicine, but it has a blood pressure-elevating effect, myocardial damage, and wateremia (Harders, H. & Rausch-Stroomann, JG, Munch. Med. Wschr. 95, 580 (1953)), low Potassiumemia, decreased plasma renin activity, pseudoaldosteronism, relaxed limb paralysis (Conn, JW, Rovner, DR & Cohen, EL, J. Am. Med. Assoc. 205, 492 (1968)), urine It has side effects such as decreased aldosterone excretion, edema, headache, lethargy (above, Epstein, MT, et al., Brit. Med. J., 1, 488 (1977)), and 150 times sweeter than sucrose. There is.
グリチルリチンの混入は、甘草疎水性抽出物のもつ種々の効果を阻害したり、上記副作用や強い甘さのために食品等としての利用に不利を生じる。そのような観点から、本発明の筋肉増量剤における甘草疎水性抽出物中のグリチルリチン含量は、好ましくは０．５重量％以下、より好ましくは０．２重量％以下、さらに好ましくは０．０１重量％未満あるいは検出限界以下（実質的にグリチルリチンを含まない）である。得られる甘草疎水性抽出物中の有効成分含量を高め、且つ、グリチルリチン等の水溶性不純物含量を低く抑えるためには、非水溶剤による抽出時に共存する水分含量を低くするのが好ましい。そのためには、上記のように抽出溶媒として含水率が低い非水溶剤を使用するだけでなく、一般に、極力乾いた甘草を原料とするのが好ましい。また、甘草の形態として、全表面積に占める皮の面積の割合が高いもの、普通３割以上、好ましくは５割以上、より好ましくは７割以上、とりわけ８割以上、なかんずく９割以上のものを使用するのが好ましい。しかしながら、甘草はいうまでもなく植物体であり、極力乾いた甘草を得るためには、通常行われている天日干し等では必ずしも十分ではなく、乾燥器等の使用が必要となる。これは、工業的規模での生産上、大きな難点となる。また、水を含まないあるいは含水率の低い非水溶剤を最初に使用したとしても、用いる甘草や作業環境からの水分の混入を完全に防止することが困難なために、抽出後は水分含量の増加した非水溶剤として回収される。回収された非水溶剤の水分含量が１５重量％を超えるとそのままリサイクル出来ないため、非水溶剤を使い捨てにするか、あるいは、無水化のための特殊で高価な精製設備が必要となり、いずれにせよ、製造コストの上昇につながる。 The incorporation of glycyrrhizin inhibits various effects of the licorice hydrophobic extract, and causes disadvantages in use as a food because of the above-mentioned side effects and strong sweetness. From such a viewpoint, the glycyrrhizin content in the licorice hydrophobic extract in the muscle bulking agent of the present invention is preferably 0.5% by weight or less, more preferably 0.2% by weight or less, and still more preferably 0.01% by weight. % Or below the detection limit (substantially does not contain glycyrrhizin). In order to increase the active ingredient content in the obtained licorice hydrophobic extract and to keep the content of water-soluble impurities such as glycyrrhizin low, it is preferable to reduce the water content coexisting during extraction with a non-aqueous solvent. For that purpose, it is preferable not only to use a non-aqueous solvent having a low water content as an extraction solvent as described above, but generally to use licorice as dry as possible as a raw material. In addition, the licorice form has a high ratio of the skin area to the total surface area, usually 30% or more, preferably 50% or more, more preferably 70% or more, particularly 80% or more, especially 90% or more. It is preferred to use. However, licorice is, of course, a plant, and in order to obtain licorice as dry as possible, it is not always sufficient to carry out sundrying or the like that is usually performed, and it is necessary to use a dryer or the like. This is a major difficulty in production on an industrial scale. In addition, even if a non-aqueous solvent containing no water or having a low water content is used for the first time, it is difficult to completely prevent moisture from being used in licorice and the working environment. It is recovered as an increased non-aqueous solvent. If the water content of the recovered non-aqueous solvent exceeds 15% by weight, it cannot be recycled as it is, so the non-aqueous solvent must be made disposable or a special and expensive purification facility for dehydration is required. In any case, it leads to an increase in manufacturing costs.
また、特に水溶性の有機溶剤を抽出溶媒として得られる甘草疎水性抽出物は、水及び一般的な油にはほとんど溶解せず、有機溶剤抽出物のままでは固結し易く着色する等、不安定なことが知られている為、使い易く且つ安定な状態に製剤化することが必要とされる。また、抽出に有機溶剤を使用することから、製造コストが高く、環境への負荷も大きい等の問題もある
そのような観点から、本発明においては、抽出に用いる非水溶剤として２種類の溶剤を使用し、甘草を第１の非水溶剤と接触させて得られる抽出物に、更に別の第２の非水溶剤を接触させるという、２段階の抽出を行うことが好ましい。
このとき、最初の抽出に使用される第１の非水溶剤としては、有機溶剤が好ましい。この場合の有機溶剤としては特に限定されず、先に抽出溶媒として述べたような有機溶剤が使用できるが、なかでもメタノール、エタノール、プロパノール、ブタノール、アセトン、ヘプタン、ヘキサン、グリセリン、脂肪酸エステル、ジエチルエーテル、シクロヘキサンまたはプロピレングリコールなどが好ましく、エタノールがより好ましく用いられる。
また２段階目の抽出に用いる第２の非水溶剤としては油脂が好ましい。特に、油脂として多価アルコール脂肪酸エステルを含む油脂を用いることにより好適に上述の目的を達成し、さらにはそのままであらゆる用途にも使用できる油脂組成物とすることができる。
さらに、前記多価アルコール脂肪酸エステルは油脂中に１０重量％以上含有されているのが好ましい。油脂中の多価アルコール脂肪酸エステル含量が１０重量％以上の場合に、特に、甘草疎水性抽出物を抽出する効果が十分に発揮される。この場合の多価アルコール脂肪酸エステルとしては、同一分子内に水酸基を２個以上有するアルコールの脂肪酸エステルであれば特に限定されず、例えば、グリセリン、ポリグリセリン、糖、糖アルコール、ポリソルベート等の多価アルコールの脂肪酸エステル等が挙げられる。本発明において使用される多価アルコール脂肪酸エステルとしては、グリセリン脂肪酸エステルが好ましく、さらには中鎖脂肪酸トリグリセリドまたは中鎖脂肪酸トリグリセリドを主成分とするグリセリン脂肪酸エステルが好ましい。第２の非水溶剤として使用される油脂中の中鎖脂肪酸トリグリセリドの含有量は約５０重量％以上が好ましく、約７０重量％以上がより好ましい。ここでの中鎖脂肪酸トリグリセリドは、炭素原子数約６〜１２の脂肪酸を構成脂肪酸とするものであれば、その脂肪酸の構成比率は特に限定されないが、炭素原子数約８〜１０の脂肪酸の構成比率が約５０重量％以上であるものが好ましく、約７０重量％以上であるものがより好ましい。また、約２０℃での比重が約０．９４〜０．９６、約２０℃での粘度が約２３〜２８ｃＰの中鎖脂肪酸トリグリセリドがさらに好ましい。また、中鎖脂肪酸トリグリセリドは、天然由来のものやエステル交換などにより調製したものなど、いずれも使用することができる。
In particular, a licorice hydrophobic extract obtained by using a water-soluble organic solvent as an extraction solvent is hardly soluble in water and general oils, and is not easily dissolved in an organic solvent extract. Since it is known to be stable, it is necessary to formulate it in an easy-to-use and stable state. In addition, since an organic solvent is used for extraction, there are problems such as high production costs and a large environmental load. From such a viewpoint, in the present invention, two types of solvents are used as the nonaqueous solvent for extraction. It is preferable to carry out a two-stage extraction in which an extract obtained by contacting licorice with a first nonaqueous solvent is further contacted with another second nonaqueous solvent.
At this time, the first non-aqueous solvent used for the first extraction is preferably an organic solvent. The organic solvent in this case is not particularly limited, and organic solvents such as those described above as the extraction solvent can be used. Among them, methanol, ethanol, propanol, butanol, acetone, heptane, hexane, glycerin, fatty acid ester, diethyl Ether, cyclohexane, propylene glycol and the like are preferable, and ethanol is more preferably used.
Moreover, fats and oils are preferable as the second non-aqueous solvent used for the second stage extraction. In particular, by using fats and oils containing polyhydric alcohol fatty acid esters as fats and oils, the above-mentioned object can be suitably achieved, and furthermore, the fat and oil composition can be used as it is for any application.
Further, the polyhydric alcohol fatty acid ester is preferably contained in the oil or fat in an amount of 10% by weight or more. When the content of the polyhydric alcohol fatty acid ester in the fat is 10% by weight or more, the effect of extracting the licorice hydrophobic extract is sufficiently exhibited. The polyhydric alcohol fatty acid ester in this case is not particularly limited as long as it is an alcohol fatty acid ester having two or more hydroxyl groups in the same molecule. For example, polyhydric alcohol such as glycerin, polyglycerin, sugar, sugar alcohol, polysorbate and the like Examples include fatty acid esters of alcohol. The polyhydric alcohol fatty acid ester used in the present invention is preferably a glycerin fatty acid ester, and more preferably a medium-chain fatty acid triglyceride or a glycerin fatty acid ester mainly composed of a medium-chain fatty acid triglyceride. The content of medium-chain fatty acid triglycerides in the fat used as the second non-aqueous solvent is preferably about 50% by weight or more, more preferably about 70% by weight or more. The medium-chain fatty acid triglyceride here is not particularly limited as long as the fatty acid having about 6 to 12 carbon atoms is a constituent fatty acid, but the fatty acid has about 8 to 10 carbon atoms. The ratio is preferably about 50% by weight or more, more preferably about 70% by weight or more. Further, a medium-chain fatty acid triglyceride having a specific gravity at about 20 ° C. of about 0.94 to 0.96 and a viscosity at about 20 ° C. of about 23 to 28 cP is more preferable. Moreover, as the medium chain fatty acid triglyceride, any of naturally derived ones and those prepared by transesterification can be used.
また、本発明において、多価アルコール脂肪酸エステルは、脂肪酸部分グリセリドまたは脂肪酸部分グリセリドを主成分とするグリセリン脂肪酸エステルであってもよい。その場合、第２の非水溶剤として使用される油脂中の脂肪酸部分グリセリドの含有量は約５０重量％以上が好ましく、約７０重量％以上がより好ましい。ここでの脂肪酸部分グリセリドとは、ジグリセリド（１，２−ジアシルグリセロール、１，３−ジアシルグリセロール）又はモノグリセリド（１−モノアシルグリセロール、２−モノアシルグリセロール）であり、いずれを用いても良いし、両者が混合されたものを用いても良く、構成脂肪酸についても特に限定されないが、加工性の観点から不飽和脂肪酸および／または中鎖脂肪酸を構成脂肪酸とするジグリセリドが好ましい。また、脂肪酸部分グリセリドは、天然由来のものやエステル交換などにより調製したものなど、いずれも使用することができる。 In the present invention, the polyhydric alcohol fatty acid ester may be a fatty acid partial glyceride or a glycerin fatty acid ester mainly composed of a fatty acid partial glyceride. In that case, the content of the fatty acid partial glyceride in the fat used as the second non-aqueous solvent is preferably about 50% by weight or more, more preferably about 70% by weight or more. The fatty acid partial glycerides here are diglycerides (1,2-diacylglycerol, 1,3-diacylglycerol) or monoglycerides (1-monoacylglycerol, 2-monoacylglycerol), and any of them may be used. A mixture of the two may be used, and the constituent fatty acid is not particularly limited, but diglycerides having an unsaturated fatty acid and / or a medium chain fatty acid as the constituent fatty acid are preferred from the viewpoint of processability. In addition, as the fatty acid partial glyceride, any of those derived from nature, those prepared by transesterification, and the like can be used.
さらに、本発明で使用される油脂は、上記の中鎖脂肪酸トリグリセリドと脂肪酸部分グリセリドが混合されたものも用いることもできる。 Furthermore, as the fats and oils used in the present invention, those obtained by mixing the medium chain fatty acid triglyceride and the fatty acid partial glyceride may be used.
本発明において、甘草を上記のように２種類の非水溶剤を使用して２段階抽出する方法は特に限定されないが、例えば、上記１回目の抽出、好ましくは、甘草を有機溶剤と接触・混合させることで抽出して得られた甘草有機溶媒抽出物を、第２の非水溶剤、好ましくは油脂に溶解することによって得ることが出来る。この場合、甘草有機溶媒抽出物は抽出液の状態でも溶剤を除去したものでもどちらでもかまわない。甘草有機溶媒抽出物の第２の非水性溶剤への溶解は、通常の撹拌又は混合などの操作により実施できるが、撹拌又は混合などの操作により甘草有機溶媒抽出物を油脂に溶解した後に、ろ過又は遠心分離などの操作により油脂に不溶な不純物を除去することがグリチルリチンなどの水溶性成分の含有量を極力低くすることが出来る点で望ましい。抽出効率を上げる為に、好ましくは３０〜１００℃ 、より好ましくは４０〜９０℃に加温して混合攪拌することが好ましく、加温による劣化を防ぐ為に、減圧下又は窒素気流下で混合攪拌を行うことがさらに好ましい。また、混合攪拌時間としては、特に限定されないが、好ましくは１時間以上、より好ましくは１〜５時間、さらに好ましくは１〜３時間である。或いは、ＷＯ０３／８４５５６記載の方法も好適に使用できる。例えば、甘草原料から直接有機溶剤と油脂により抽出することも可能であるが、甘草を有機溶剤で抽出して得られる抽出液に、油脂を混合した後、有機溶剤を除去することによっても得ることができ、好ましくは、甘草原料をエタノールと接触混合後、不要成分を除去して得られる甘草抽出物のエタノール溶液に、油脂、好ましくは中鎖脂肪酸トリグリセリドを混合した後、エタノールを除去することによって得ることが出来る。さらに、本発明では、これらの甘草疎水性抽出物と油脂の混合物に対してさらに油脂を添加して、甘草疎水性抽出物と油脂の組成比を調整しても良い。 In the present invention, there are no particular limitations on the method of extracting licorice in two stages using two types of non-aqueous solvents as described above. For example, the first extraction described above, preferably, licorice is contacted and mixed with an organic solvent. The licorice organic solvent extract obtained by extraction can be obtained by dissolving in a second non-aqueous solvent, preferably an oil or fat. In this case, the licorice organic solvent extract may be in the form of an extract or from which the solvent is removed. Dissolution of the licorice organic solvent extract in the second non-aqueous solvent can be carried out by ordinary operations such as stirring or mixing, but the licorice organic solvent extract is dissolved in fats and oils by operation such as stirring or mixing, followed by filtration. Alternatively, it is desirable to remove impurities that are insoluble in fats and oils by an operation such as centrifugation because the content of water-soluble components such as glycyrrhizin can be reduced as much as possible. In order to increase the extraction efficiency, it is preferable that the mixture is heated to 30 to 100 ° C., more preferably 40 to 90 ° C., and preferably mixed and stirred. In order to prevent deterioration due to heating, mixing is performed under reduced pressure or in a nitrogen stream. More preferably, stirring is performed. The mixing and stirring time is not particularly limited, but is preferably 1 hour or longer, more preferably 1 to 5 hours, and further preferably 1 to 3 hours. Or the method of WO03 / 84556 can also be used conveniently. For example, it is possible to extract directly from a licorice raw material with an organic solvent and fat, but it can also be obtained by mixing the fat and oil into an extract obtained by extracting licorice with an organic solvent and then removing the organic solvent. Preferably, by mixing the licorice raw material with ethanol and then mixing unnecessary oil and fat, preferably medium-chain fatty acid triglycerides, in ethanol solution of licorice extract obtained by contact mixing with ethanol, and then removing ethanol. Can be obtained. Furthermore, in this invention, you may add fats and oils with respect to the mixture of these licorice hydrophobic extracts and fats and oils, and may adjust the composition ratio of a licorice hydrophobic extract and fats and oils.
一般に、疎水性の甘草疎水性抽出物は、粉末状態において不安定であり、エタノールなどの有機溶媒へ溶解しても安定性は改善されない。しかし、該抽出物を上記の好ましい方法により油脂に溶解することでその安定性を改善することができる。また、甘草疎水性抽出物は難水溶性であることから、油脂に溶解した状態で使用することにより、その吸収性が向上することも期待できる。その場合、抽出物の性状は、液状又はスラリー状となるのが好ましい。 Generally, a hydrophobic licorice hydrophobic extract is unstable in a powder state, and its stability is not improved even when dissolved in an organic solvent such as ethanol. However, the stability can be improved by dissolving the extract in fats and oils by the preferred method described above. Moreover, since the licorice hydrophobic extract is sparingly water-soluble, it can be expected that its absorbability is improved by using it in a state dissolved in fats and oils. In that case, the properties of the extract are preferably liquid or slurry.
このような２段階抽出を行うことにより、有効成分含量が高く、水溶性不純物含量の低い高品質の甘草疎水性抽出物を好適に取得できる。上記２段階抽出によって得られる甘草疎水性抽出物中のグリチルリチン含量は、第１の非水溶剤として多少水を含有する有機溶剤を使用し、原料となる甘草の乾燥が不十分な場合でも、好ましくは０．５重量％以下、より好ましくは０．２重量％以下、さらに好ましくは０．０１重量％未満あるいは検出限界以下と最小化することができる。また、２段階抽出を行うことで、甘草を特別に乾燥することなく、抽出溶媒として安価な含水した有機溶媒を使用する場合においても高品質の抽出物を好適に取得できるため、製造プロセスの簡略化とコスト削減の点で、非常に大きなメリットが期待できる。 By performing such two-stage extraction, a high-quality licorice hydrophobic extract having a high active ingredient content and a low water-soluble impurity content can be suitably obtained. The glycyrrhizin content in the licorice hydrophobic extract obtained by the above two-stage extraction is preferable even when an organic solvent containing some water is used as the first non-aqueous solvent and the licorice used as a raw material is insufficiently dried. Can be minimized to 0.5 wt% or less, more preferably 0.2 wt% or less, even more preferably less than 0.01 wt% or below the detection limit. In addition, by performing two-stage extraction, a high quality extract can be suitably obtained even when an inexpensive organic solvent containing water is used as an extraction solvent without specially drying licorice, thus simplifying the manufacturing process. A great advantage can be expected in terms of cost and cost reduction.
上記のような方法によって得られる甘草疎水性抽出物を含有する本発明の筋肉増量剤の形態は特に限定されず、例えば、ハードカプセル、ソフトカプセル、錠剤、散剤、シロップ、ドリンク剤などの形態で、医薬品やその他の用途に利用することができる。また、グラブレン、グラブリジン、グラブロール、３’−ヒドロキシ−４’−Ｏ−メチルグラブリジン、４’−Ｏ−メチルグラブリジン、ヒスパグラブリジンＢよりなる群より選ばれた少なくとも１つの化合物が溶解している油脂を、そのまま単独で調理用、ソフトカプセル製剤用などとして利用することもできる。さらに、上記好ましい方法によって得られる甘草疎水性抽出物と油脂の混合物は、油性の対象物と自由に混和することができるため、目的に応じて他の油脂と混合して物性を調整することが可能である。この場合、他の油脂は食品又は医薬品であることが好ましく、その種類及び使用量は、個々の製品に要求される物性や使用温度域などの諸条件を考慮して決定され、その種類及び使用量を調整することにより稠度や融点などの特性をコントロールすることができる。例えば、コーン油、ナタネ油、ハイエルシンナタネ油、大豆油、オリーブ油、紅花油、綿実油、ヒマワリ油、米糠油、パーム油、パーム核油などの植物油、魚油、牛脂、豚脂、乳脂、卵黄油などの動物油、又はこれらを原料として分別、水添、エステル交換などを行った油脂、あるいはこれらの混合油を使用して油脂組成物とすることができる。このようにして得られる油脂組成物は、サラダ油やフライ油などの液状油脂、マーガリンやショートニングなどの可塑性油脂としての利用や、油中水型エマルジョン、水中油型エマルジョンへ利用することができる。 The form of the muscle bulking agent of the present invention containing the licorice hydrophobic extract obtained by the above method is not particularly limited. For example, in the form of hard capsule, soft capsule, tablet, powder, syrup, drink, etc. And can be used for other purposes. Oils and fats in which at least one compound selected from the group consisting of grabrene, grabridine, grabrol, 3′-hydroxy-4′-O-methyl grabridine, 4′-O-methyl grabridine, and Hispa grabridin B is dissolved Can be used alone for cooking or for soft capsule preparations. Furthermore, since the mixture of the licorice hydrophobic extract obtained by the said preferable method and fats and oils can be freely mixed with an oily object, it can mix with other fats and oils according to the objective, and can adjust a physical property. Is possible. In this case, it is preferable that the other fats and oils are foods or pharmaceuticals, and the type and use amount thereof are determined in consideration of various conditions such as physical properties and use temperature range required for each product. By adjusting the amount, characteristics such as consistency and melting point can be controlled. For example, vegetable oil such as corn oil, rapeseed oil, Haier rapeseed oil, soybean oil, olive oil, safflower oil, cottonseed oil, sunflower oil, rice bran oil, palm oil, palm kernel oil, fish oil, beef tallow, lard, milk fat, egg yolk oil An oil composition can be obtained by using animal oils such as these, oils and fats that have been subjected to fractionation, hydrogenation, transesterification, etc., or mixed oils thereof. The oil / fat composition thus obtained can be used as liquid oil / fat such as salad oil and frying oil, plastic oil / fat such as margarine and shortening, water-in-oil emulsion, and oil-in-water emulsion.
さらに、栄養強化を目的として、ビタミンＡ，Ｄ，Ｅなどの各種ビタミン類を添加、併用してもよいし、呈味剤としての各種塩類、各種香料、乳関連物質、例えば、全脂粉乳、脱脂粉乳、発酵乳、乳脂肪などを添加、併用してもよい。また、上記以外の原材料として、通常の油中水型エマルジョン、水中油型エマルジョンに使用される酸化防止剤、着色剤などを全て使用することができる。 Furthermore, for the purpose of fortification, various vitamins such as vitamins A, D, and E may be added and used together. Various salts as flavoring agents, various flavorings, milk-related substances such as whole milk powder, You may add skim milk powder, fermented milk, milk fat, etc., and may use together. Further, as raw materials other than the above, all of the antioxidants, colorants and the like used in ordinary water-in-oil emulsions and oil-in-water emulsions can be used.
また、本発明の筋肉増量剤は、上記甘草疎水性抽出物の他に、飲食用または医薬用に許容される担体を含みうる。該医薬用担体は、例えば経口、経腸、経皮、皮下、または非経腸投与のため好適な任意の不活性、有機または無機材料であり得、限定されないが水、ゼラチン、アラビアガム、ラクトース、微結晶性セルロース、スターチ、ナトリウムスターチグリコレート、燐酸水素カルシウム、ステアリン酸マグネシウム、タルク、およびコロイド性二酸化ケイ素等であることができる。そのような組成物はまた、他の薬理学的活性な製剤成分、および通常の添加物、例えば安定剤、湿潤剤、乳化剤、香味剤、および緩衝剤等を含みうる。 In addition to the licorice hydrophobic extract, the muscle bulking agent of the present invention may contain a carrier that is acceptable for food and drink or for medicine. The pharmaceutical carrier can be any inert, organic or inorganic material suitable for oral, enteral, transdermal, subcutaneous, or parenteral administration, including but not limited to water, gelatin, gum arabic, lactose , Microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talc, colloidal silicon dioxide, and the like. Such compositions may also contain other pharmacologically active pharmaceutical ingredients, and conventional additives such as stabilizers, wetting agents, emulsifying agents, flavoring agents, buffering agents and the like.
本発明において、筋肉増量効果の確認は、動物（マウス、ラットなど）を用いて、被検サンプルを与えて、筋肉重量を測定する方法で行うことができる。サンプルの与え方は餌あるいは飲料水中に混入させても良いし、またゾンデなどを用いて強制的に経口投与しても構わない。被験サンプルの投与タイミングを工夫することで筋肉量の増加を確認することができる。また、ヒトに実際に投与することでその効果を確認することも出来る。 In the present invention, the effect of increasing the muscle mass can be confirmed by a method in which a test sample is given using an animal (mouse, rat, etc.) and the muscle weight is measured. The sample may be fed into food or drinking water, or may be forcibly orally administered using a sonde or the like. An increase in muscle mass can be confirmed by devising the administration timing of the test sample. Moreover, the effect can also be confirmed by actually administering to a human.
本発明の筋肉増量剤は、従来筋肉増量に必要であった特定の運動を行わずとも、筋肉増量効果を発揮できる。従って、運動による負荷が困難な投与対象、例えば寝たきりの病人や一定期間安静が必要な怪我や病気を有する患者、激しい運動が困難な老人などに投与することでも、筋肉量の増加または維持が期待でき、寝たきり防止や筋肉萎縮の防止効果も期待できる。また、日常的な運動と組み合わせて投与することでも、筋肉増量効果を発揮できる。ここでいう日常的な運動とは、ジョギングや柔軟体操、エステ体操、その他、趣味のスポーツへの参加だけでなく、通勤、仕事や家事等における軽作業も含まれる。日常的な運動における具体的な消費カロリーとしては、対象者の性別や年齢にもより特に限定されないが、例えば、３０分あたりの消費カロリーとして５０ｋｃａｌ以上、好ましくは６０ｋｃａｌ以上、より好ましくは８０ｋｃａｌ以上、上限としては１４０ｋｃａｌまでの運動や作業が日常的な運動に相当する。日常的な運動を行う程度も特に限定されず、対象者の年齢や体重、目的、生活習慣に応じて適宜設定すればよいが、例えば１日あたりの日常的な運動を含めた総消費カロリーとして１５００ｋｃａｌ以上、好ましくは１７００ｋｃａｌ程度以上となるようにすればよい。上限も特に限定されず、総消費カロリーとして多い方がより高い効果が得られる傾向があるのは言うまでもないが、本発明の筋肉増量剤を摂取する場合には、例えば２３００ｋｃａｌ程度、好ましくは２１００ｋｃａｌ程度の総消費カロリーでも十分に効果が得られる。 The muscle bulking agent of the present invention can exert a muscle weight gain effect without performing the specific exercise conventionally required for muscle weight gain. Therefore, it is expected to increase or maintain muscle mass even when administered to subjects who are difficult to exercise due to exercise, such as bedridden sick people, patients with injuries or illnesses that need to rest for a certain period of time, elderly people who have difficulty with intense exercise, etc. It can also be expected to prevent bedridden and prevent muscle atrophy. In addition, administration in combination with daily exercise can also exert a muscle gain effect. Daily exercises here include not only jogging, flexible gymnastics, esthetic gymnastics, and other hobby sports, but also light work such as commuting, work and housework. Specific calorie consumption in daily exercise is not particularly limited by the gender and age of the subject, for example, as calorie consumption per 30 minutes 50 kcal or more, preferably 60 kcal or more, more preferably 80 kcal or more, As the upper limit, exercise and work up to 140 kcal correspond to daily exercise. The degree of performing daily exercise is not particularly limited, and may be set as appropriate according to the age, weight, purpose, and lifestyle of the subject. For example, the total calories consumed including daily exercise per day It may be 1500 kcal or more, preferably about 1700 kcal or more. The upper limit is not particularly limited, and it goes without saying that the higher the total calorie consumption, the higher the effect tends to be obtained. However, when taking the muscle bulking agent of the present invention, for example, about 2300 kcal, preferably about 2100 kcal. Even with the total calories burned, the effect can be obtained sufficiently.
また、本発明の筋肉増量剤は、従来筋肉増量に有効的とされるレジスタンス運動と組み合わせて投与することでも、より好ましく効果を発揮しうる。ここでいうレジスタンス運動とは筋肉に一定の負荷をかけて行われる運動のことであり、負荷をかける方法としては特に限定されないが、バーベルやマシンなどのほか、適当な重量物や水、エキスパンダーやゴムチューブなど利用することが出来る。 In addition, the muscle bulking agent of the present invention can exert a more preferable effect even when administered in combination with a resistance exercise that has been conventionally effective for muscle weight gain. The resistance exercise here is an exercise that is performed with a certain load on the muscle, and the method of applying the load is not particularly limited, but besides barbells and machines, appropriate heavy objects, water, expanders, A rubber tube can be used.
上記運動と本発明の筋肉増量剤の組み合わせとしては、本発明の筋肉増量剤の摂取と、上記運動を一定期間内で併用する形態であれば特に限定されず、一日の摂取量と運動量は制限されない。また、本発明においては運動による負荷が困難な投与対象に投与されるために、あるいは上記日常的な運動やレジスタンス運動と組み合わされるために、その使用形態がカタログ等で例示・推奨されたり、医者やスポーツインストラクターやその他専門家などから好ましい方法として勧められたりすることもあるが、それらも本発明の範疇である。 The combination of the above exercise and the muscle bulking agent of the present invention is not particularly limited as long as it is a form in which the intake of the muscle bulking agent of the present invention and the above exercise are used in combination within a certain period. Not limited. In addition, in the present invention, in order to be administered to an administration subject that is difficult to load due to exercise, or to be combined with the above-mentioned daily exercise or resistance exercise, its use form is exemplified and recommended in a catalog or the like, or a doctor May be recommended as a preferable method from sports instructors and other professionals, and these are also within the scope of the present invention.
さらに、本発明の筋肉増量剤の有効成分である甘草疎水性抽出物は、筋肉増量だけでなく、メタボリックシンドロームの主な原因となる体脂肪蓄積抑制、体脂肪分解促進効果、およびエネルギー産生促進効果（ＷＯ２００８−１４３１８２）、血糖値の上昇抑制効果（Ｂｉｏｌ．Ｐｈａｒｍ．Ｂｕｌｌ．２７（１１）１７７５−１７７８（２００４））、更には血液中中性脂肪値の上昇抑制や、血液中遊離脂肪酸値の上昇を抑制する優れた効果も有する。すなわち、本発明の筋肉増量剤は、筋肉量の増加だけでなく、肥満、糖尿病および高脂血症の予防目的としても利用できる。
本発明の筋肉増量剤を摂取する方法は特に限定されないが、日常的に継続的に摂取するのが好ましい。摂取経路も特に限定されないが、経口投与が簡便で好ましい。摂取量は特に限定されないが、甘草疎水性抽出物の量に換算して、成人で３０〜６００ｍｇ／回または３０〜６００ｍｇ／日の範囲の量が好ましく、５０ｍｇ〜５００ｍｇ／回または５０〜５００ｍｇ／日の範囲の量がより好ましく、８０ｍｇ〜３００ｍｇ／回または８０〜３００ｍｇ／日の範囲の量がさらに好ましい。
また、本発明の筋肉増量剤はヒトだけでなく、食肉の生産性向上を目的として家畜に投与したり、競走馬の成績向上目的や、ペットの健康維持の目的でも使用できる。この場合、直接経口投与することも出来るし、飼料に混合することで投与することも出来る。
Furthermore, the licorice hydrophobic extract, which is an active ingredient of the muscle bulking agent of the present invention, not only increases the muscle weight but also suppresses body fat accumulation, the body fat degradation promoting effect, and the energy production promoting effect, which are the main causes of metabolic syndrome. (WO 2008-143182), blood glucose level increase inhibitory effect (Biol. Pharm. Bull. 27 (11) 1775-1778 (2004)), blood blood neutral fat level increase suppression, blood free fatty acid level It also has an excellent effect of suppressing the rise. That is, the muscle bulking agent of the present invention can be used not only for increasing muscle mass but also for the purpose of preventing obesity, diabetes and hyperlipidemia.
The method for ingesting the muscle bulking agent of the present invention is not particularly limited, but it is preferable to ingest it on a daily basis. The intake route is not particularly limited, but oral administration is simple and preferable. The amount of intake is not particularly limited, but in terms of the amount of licorice hydrophobic extract, the amount in the range of 30 to 600 mg / dose or 30 to 600 mg / day is preferable for adults, and 50 mg to 500 mg / dose or 50 to 500 mg / d An amount in the range of days is more preferred, and an amount in the range of 80 mg to 300 mg / dose or 80 to 300 mg / day is even more preferred.
The muscle bulking agent of the present invention can be used not only for humans but also for livestock for the purpose of improving meat productivity, for the purpose of improving the performance of racehorses, and for the purpose of maintaining the health of pets. In this case, it can be administered directly orally or by mixing with feed.
以下に、実施例を挙げて本発明をさらに具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples.
甘草（グリキリーザ・グラブラ）９．８５ｋｇに９５％エタノール（含水率５重量％）４９．２５Ｌを加え、４５℃、２時間で２回抽出し、次いで濃縮して、濃縮液４．４Ｌを得た。そのうち３Ｌを更に濃縮して、活性炭処理し、さらに濃縮して、甘草疎水性抽出物を含有したエタノール溶液８１１．２ｇを得た。 49.25 L of 95% ethanol (water content 5% by weight) was added to 9.85 kg of licorice (Glyquiryza grabra), extracted twice at 45 ° C. for 2 hours, and then concentrated to obtain 4.4 L of a concentrated solution. . Among them, 3 L was further concentrated, treated with activated carbon, and further concentrated to obtain 81.2 g of an ethanol solution containing a licorice hydrophobic extract.
上記のエタノール溶液６２９．２ｇ（甘草疎水性抽出物１２５．８ｇを含有）と中鎖脂肪酸トリグリセリド（ＭＣＴ、水分含有量約０容量％）（アクターＭ−２、理研ビタミン（株）製、脂肪酸組成はＣ８：Ｃ１０＝９９：１）１８７．６ｇを混合し、約８０℃に保温しながら約１時間撹拌した後、減圧濃縮によりエタノールを除去した。吸引ろ過により不溶分を分離し、ろ別後のろ液にＭＣＴ４５．７ｇを更に添加して、ＭＣＴ溶液２９７．０ｇを得た。得られたＭＣＴ溶液１ｇをＨＰＬＣ用メタノールに溶解し、全量を１００ｍｌとし、この溶液を試料として下記の条件にてＨＰＬＣ分析を行った結果、前記ＭＣＴ溶液１ｇあたりにグラブレン、グラブリジン、グラブロール、４’−Ｏ−メチルグラブリジンがそれぞれ６．６ｍｇ、３０．８ｍｇ、１２．６ｍｇ、３．７ｍｇ含まれていることがわかった。また、該ＭＣＴ溶液中の甘草疎水性抽出物の含有量は約３０重量％であった。 629.2 g of ethanol solution (containing 125.8 g of licorice hydrophobic extract) and medium-chain fatty acid triglyceride (MCT, water content of about 0% by volume) (actor M-2, manufactured by Riken Vitamin Co., Ltd., fatty acid composition Was mixed with 187.6 g of C8: C10 = 99: 1) and stirred for about 1 hour while being kept at about 80 ° C., and then ethanol was removed by concentration under reduced pressure. Insoluble matter was separated by suction filtration, and 45.7 g of MCT was further added to the filtrate after filtration to obtain 297.0 g of MCT solution. 1 g of the obtained MCT solution was dissolved in methanol for HPLC to make a total amount of 100 ml, and this solution was used as a sample for HPLC analysis under the following conditions. As a result, grabrene, grabridine, grabrol, 4 g It turned out that 6.6 mg, 30.8 mg, 12.6 mg, and 3.7 mg of '-O-methyl glabridine are contained, respectively. The content of the licorice hydrophobic extract in the MCT solution was about 30% by weight.
（ＨＰＬＣ分析条件）
分析カラムは、Ｊ’ｓｐｈｅｒｅ ＯＤＳ−Ｈ８０，４．６×２５０ｍｍ（ワイエムシィ）をカラム温度４０℃にて使用した。移動相は、２０ｍＭリン酸水溶液に対してアセトニトリルの比率を分析開始から２０ｍｉｎまで３５％で一定とし、２０ｍｉｎ以降７５ｍｉｎ後に７０％となるように一定の比率で上昇させ、７５ｍｉｎから８０ｍｉｎまで８０％で一定とするグラジエント条件で、流速１ｍｌ／ｍｉｎとした。注入量は２０μｌとし、検出波長は２５４ｎｍとした。各化合物の保持時間は、グラブレンが４０．０ｍｉｎ、グラブリジンが５０．２ｍｉｎ、グラブロールが５８．３ｍｉｎ、４’−Ｏ−メチルグラブリジンが６６．８ｍｉｎである。
(HPLC analysis conditions)
As the analytical column, J'sphere ODS-H80, 4.6 × 250 mm (YMC) was used at a column temperature of 40 ° C. In the mobile phase, the acetonitrile ratio with respect to the 20 mM phosphoric acid aqueous solution is kept constant at 35% from the start of analysis to 20 min, and is increased at a constant ratio so that it becomes 70% after 75 min after 20 min, and 80% from 75 min to 80 min. The flow rate was 1 ml / min under a constant gradient condition. The injection volume was 20 μl, and the detection wavelength was 254 nm. The retention time of each compound is 40.0 min for grabrene, 50.2 min for grabridine, 58.3 min for grabrol, and 66.8 min for 4′-O-methyl grabridine.
（比較例１）
甘草（グリキリーザ・グラブラ）１．０ｋｇに８０％エタノール（含水率２０重量％）４．９Ｌを加え、４５℃、２時間で２回抽出し、次いで濃縮して、濃縮液０．４Ｌを得た。更に濃縮して、活性炭処理し、さらに濃縮して、甘草抽出物を含有したエタノール溶液９０ｇを得た。最終的には、エバポレーターにてエタノールを蒸発させて、甘草抽出物１８．１を得た。この抽出物とＭＣＴを３：７の割合で混合し溶解した甘草抽出物溶液を得た。
(Comparative Example 1)
4.9 L of 80% ethanol (water content 20% by weight) was added to 1.0 kg of licorice (Glyquiryza grabra), extracted twice at 45 ° C. for 2 hours, and then concentrated to obtain 0.4 L of a concentrated solution. . The solution was further concentrated, treated with activated carbon, and further concentrated to obtain 90 g of an ethanol solution containing a licorice extract. Finally, ethanol was evaporated by an evaporator to obtain a licorice extract 18.1. A licorice extract solution in which this extract and MCT were mixed and dissolved at a ratio of 3: 7 was obtained.
自然発症肥満２型糖尿病モデルＫＫ−Ａｙ／Ｔａ Ｊｃｌ系雄性マウス(日本クレア) を５週齢で購入し、１週間馴化飼育した後、６週齢で実験に使用した。マウスの体重を指標にして均等となるよう６〜７匹ずつ４群に分けた。それぞれ蒸留水を５ｍＬ／Ｋｇ（体重）を連日強制経口投与した群（対照群）、比較例１で得られた甘草抽出物溶液を１．０ｇ／ｋｇ（体重）となるよう連日強制経口投与した群（比較群）、実施例１で得られた甘草疎水性抽出物を含むＭＣＴ溶液を１．０ｇ／ｋｇ（体重）となるよう連日強制経口投与した群（サンプル１．０ｇ／ｋｇ群）、実施例１で得られた甘草疎水性抽出物を含むＭＣＴ溶液を１．０％（ｗ／ｗ）となるよう飼料に混合し自由摂取させた群（サンプル１．０％混餌群）を設定した。なお試験期間中、各群のマウスはケージにて、日常的な運動を行える状態で一般的な飼育を行った。投与開始後４週間目にマウスをイソフルランで麻酔して開腹し、腹部下大静脈より全採血した後、大腿筋を採取して重量を測定した。その結果を表１及び２に示す。 Spontaneous obesity type 2 diabetes model KK- Ay / Ta Jcl male mice (CLEA Japan, Inc.) were purchased at 5 weeks of age, acclimated for 1 week, and used for experiments at 6 weeks of age. The mice were divided into 4 groups of 6-7 animals so that the body weight was equal. A group (control group) in which 5 mL / Kg (body weight) of daily distilled water was orally administered by gavage daily, and the licorice extract solution obtained in Comparative Example 1 was gavaged daily to give 1.0 g / kg (body weight). Group (comparison group), a group (sample 1.0 g / kg group) forcibly orally administered MCT solution containing the licorice hydrophobic extract obtained in Example 1 every day to 1.0 g / kg (body weight), The MCT solution containing the licorice hydrophobic extract obtained in Example 1 was mixed with the feed so as to be 1.0% (w / w), and a group (free sample group of 1.0%) was set. . During the test period, each group of mice was reared in a cage in a state where they could perform daily exercise. Four weeks after the start of administration, the mice were anesthetized with isoflurane and laparotomized. After blood was collected from the inferior vena cava, the thigh muscles were collected and weighed. The results are shown in Tables 1 and 2.
表１、表２において、対照群と比較した場合、２段階抽出による甘草疎水性抽出物を含むＭＣＴ溶液を強制経口投与した群、及び飼料に混合して自由に摂取させた群では、いずれも筋肉重量の増加が有意に認められた。しかし、甘草を８０％エタノールで抽出した甘草抽出物溶液を強制経口投与した群では筋肉重量の有意な増加は認められなかった。つまり、抽出溶媒として含水率が２０重量％のエタノールを使用して得られる甘草抽出物には十分な筋肉増量効果が認められず、抽出溶媒の含水率が本発明の効果に重要な影響を与えることが分かった。 In Tables 1 and 2, when compared with the control group, both the group in which the MCT solution containing the licorice hydrophobic extract by two-stage extraction was forcibly administered orally and the group that was freely mixed with the feed were ingested. A significant increase in muscle weight was observed. However, a significant increase in muscle weight was not observed in the group to which licorice extract solution obtained by extracting licorice with 80% ethanol by gavage was administered. That is, a licorice extract obtained by using ethanol having a water content of 20% by weight as an extraction solvent does not have a sufficient muscle weight increasing effect, and the water content of the extraction solvent has an important influence on the effect of the present invention. I understood that.
ソフトカプセル剤の製造
実施例１の甘草疎水性抽出物を含むＭＣＴ溶液を、ロータリー式ソフトカプセル製造装置を用いてゼラチン皮膜に圧入し、内容量３５０ｍｇのソフトカプセル剤を得た。
Production of Soft Capsule The MCT solution containing the licorice hydrophobic extract of Example 1 was pressed into a gelatin film using a rotary soft capsule production apparatus to obtain a soft capsule having an internal volume of 350 mg.
マーガリンの製造
硬化綿実油（商品名：スノーライト、株式会社カネカ製）８０重量部、実施例１の甘草疎水性抽出物を含むＭＣＴ溶液２０重量部、無塩バター（四つ葉乳業（株）製）１０重量部に、グリセリンモノ脂肪酸エステル（商品名：エマルジーＭＳ、理研ビタミン（株）製）０．２重量部、レシチン０．２重量部を添加し、６０℃に加熱溶解し油相を調製した。
Production of margarine 80 parts by weight of hardened cottonseed oil (trade name: Snowlight, Kaneka Co., Ltd.), 20 parts by weight of MCT solution containing the licorice hydrophobic extract of Example 1, unsalted butter (manufactured by Yotsuba Dairy Co., Ltd.) ) To 10 parts by weight, 0.2 part by weight of glycerin monofatty acid ester (trade name: Emergy MS, manufactured by Riken Vitamin Co., Ltd.) and 0.2 part by weight of lecithin are added and dissolved at 60 ° C. to prepare an oil phase. did.
調製された油相８４．９重量部に撹拌しながら水１５．１重量部を添加し、２０分間乳化を行った後、コンビネーターで冷却捏和してマーガリンを作製した。 While stirring, 15.1 parts by weight of water was added to 84.9 parts by weight of the prepared oil phase, emulsified for 20 minutes, and then cooled and kneaded with a combinator to prepare margarine.
濃縮乳の製造
実施例１の甘草疎水性抽出物を含むＭＣＴ溶液１０重量部を７０℃に加温後、レシチン０．１重量部及びポリグリセリン脂肪酸エステル０．１重量部を順次溶解して油相を作製した。
Preparation of concentrated milk After heating 10 parts by weight of the MCT solution containing the licorice hydrophobic extract of Example 1 to 70 ° C., 0.1 parts by weight of lecithin and 0.1 parts by weight of polyglycerol fatty acid ester were dissolved in order to obtain oil. A phase was prepared.
脱脂粉乳２５重量部、グリセリン脂肪酸エステル０．１重量部、ショ糖脂肪酸エステル０．１重量部を６０℃の水６４．６重量部に溶解して水相を調製した。 An aqueous phase was prepared by dissolving 25 parts by weight of skim milk powder, 0.1 part by weight of glycerin fatty acid ester and 0.1 part by weight of sucrose fatty acid ester in 64.6 parts by weight of water at 60 ° C.
調製した水相と油相を予備乳化した後、ＵＨＴ殺菌機にて１４５℃で４秒間殺菌した。次いで真空冷却した後、均質化機により１０ＭＰａの圧力で均質化し、更に１０℃までプレート冷却して加工用濃縮乳を得た。 The prepared aqueous phase and oil phase were pre-emulsified, and then sterilized with a UHT sterilizer at 145 ° C. for 4 seconds. Next, after vacuum cooling, the mixture was homogenized with a homogenizer at a pressure of 10 MPa, and further cooled to 10 ° C. to obtain concentrated milk for processing.
マヨネーズの製造
醸造酢１０重量部、食塩１重量部、砂糖０．６重量部、マスタード粉末０．２重量部、グルタミン酸ナトリウム０．２重量部を混合器の中に加え、１５〜２０℃下で攪拌・混合し水相を調製した。その後、米白絞油６８重量部、実施例１の甘草疎水性抽出物を含むＭＣＴ溶液１０重量部に卵黄１０重量部を加え、攪拌乳化して得た乳化液（１０〜１５℃）を少しずつ加えながら１５〜２０℃下で攪拌し、予備乳化した。次いで、コロイドミルを用いて仕上げ乳化を行いマヨネーズを得た。
Production of mayonnaise 10 parts by weight of brewed vinegar, 1 part by weight of salt, 0.6 parts by weight of sugar, 0.2 parts by weight of mustard powder and 0.2 parts by weight of sodium glutamate are added to the mixer at 15-20 ° C. The aqueous phase was prepared by stirring and mixing. Then, 10 parts by weight of egg yolk was added to 68 parts by weight of rice white squeezed oil and 10 parts by weight of MCT solution containing the licorice hydrophobic extract of Example 1, and a little emulsified liquid (10-15 ° C) obtained by stirring and emulsifying The mixture was stirred at 15 to 20 ° C. while adding, and pre-emulsified. Subsequently, final emulsification was performed using a colloid mill to obtain mayonnaise.
Claims (5)
The second nonaqueous solvent is, claim 3 or 4 muscle mass increase or maintenance method wherein the fat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015141552A JP6010665B2 (en) | 2011-03-03 | 2015-07-15 | Muscle bulking agent |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011046764 | 2011-03-03 | ||
| JP2011046764 | 2011-03-03 | ||
| JP2015141552A JP6010665B2 (en) | 2011-03-03 | 2015-07-15 | Muscle bulking agent |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011167412A Division JP6010281B2 (en) | 2011-03-03 | 2011-07-29 | Muscle bulking agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015232004A JP2015232004A (en) | 2015-12-24 |
| JP6010665B2 true JP6010665B2 (en) | 2016-10-19 |
Family
ID=47085425
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011167412A Active JP6010281B2 (en) | 2011-03-03 | 2011-07-29 | Muscle bulking agent |
| JP2015141552A Active JP6010665B2 (en) | 2011-03-03 | 2015-07-15 | Muscle bulking agent |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011167412A Active JP6010281B2 (en) | 2011-03-03 | 2011-07-29 | Muscle bulking agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP6010281B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200145716A (en) * | 2019-06-19 | 2020-12-30 | 영남대학교 산학협력단 | Composition for preventing or treating muscular diseases |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101652730B1 (en) * | 2015-10-08 | 2016-09-01 | 한국원자력연구원 | Method for preparation of herbal composition increased fat-soluble polyphenols, herbal composition prepared thereby, and using thereof |
| JP7282350B2 (en) * | 2017-12-06 | 2023-05-29 | 国立大学法人高知大学 | METHOD FOR PRODUCING PROTEIN GLYCATION INHIBITOR |
| WO2020256397A1 (en) * | 2019-06-19 | 2020-12-24 | 영남대학교 산학협력단 | Composition for preventing or treating muscular diseases, containing, as active ingredient, glycyrrhiza uralensis extract or compound isolated therefrom |
| JPWO2021125342A1 (en) * | 2019-12-20 | 2021-06-24 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329516B (en) * | 2000-12-12 | 2010-09-01 | Kaneka Corp | Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity |
| EP1440688A4 (en) * | 2001-10-11 | 2005-11-30 | Kaneka Corp | Peroxisome proliferator activated receptor ligands and process for producing the same |
| JP2006160655A (en) * | 2004-12-06 | 2006-06-22 | Nippon Menaade Keshohin Kk | Muscular activator |
| JP2007063161A (en) * | 2005-08-30 | 2007-03-15 | Kaneka Corp | Acute phase reactant transcription inhibition activator |
| JP2009143838A (en) * | 2007-12-13 | 2009-07-02 | Nippon Menaade Keshohin Kk | Muscle activator |
| US20090274781A1 (en) * | 2008-05-02 | 2009-11-05 | Asgen Pharmaceutical Co., Ltd. | Anti-obesity agent |
| US20100173829A1 (en) * | 2008-11-07 | 2010-07-08 | Aston University | Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof |
| JP2011001348A (en) * | 2009-05-18 | 2011-01-06 | Kaneka Corp | Formulation for prevention or alleviation of alcohol drunkenness or hangover |
-
2011
- 2011-07-29 JP JP2011167412A patent/JP6010281B2/en active Active
-
2015
- 2015-07-15 JP JP2015141552A patent/JP6010665B2/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200145716A (en) * | 2019-06-19 | 2020-12-30 | 영남대학교 산학협력단 | Composition for preventing or treating muscular diseases |
| KR20200145717A (en) * | 2019-06-19 | 2020-12-30 | 영남대학교 산학협력단 | Composition for preventing or treating muscular diseases |
| KR20200145718A (en) * | 2019-06-19 | 2020-12-30 | 영남대학교 산학협력단 | Composition for preventing or treating muscular diseases |
| KR102210503B1 (en) | 2019-06-19 | 2021-02-01 | 영남대학교 산학협력단 | Composition for preventing or treating muscular diseases |
| KR102210501B1 (en) | 2019-06-19 | 2021-02-01 | 영남대학교 산학협력단 | Composition for preventing or treating muscular diseases |
| KR102210502B1 (en) | 2019-06-19 | 2021-02-01 | 영남대학교 산학협력단 | Composition for preventing or treating muscular diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6010281B2 (en) | 2016-10-19 |
| JP2012193157A (en) | 2012-10-11 |
| JP2015232004A (en) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Paul et al. | Pomegranate seed oil in food industry: Extraction, characterization, and applications | |
| JP4685355B2 (en) | Process for producing oil and fat composition containing licorice hydrophobic component | |
| JP6010665B2 (en) | Muscle bulking agent | |
| KR101262686B1 (en) | Composition for body fat reduction | |
| KR20170028486A (en) | Composition for Preventing, Treating or Improving Menopausal Syndrome comprising Sparassis crispa Wulf.: Fr. and Lactic Acid Bacteria as Active Ingredient | |
| KR20040095263A (en) | Body temperature elevating agents | |
| US10653655B2 (en) | Composition for preventing or improving peripheral neuropathy | |
| JPWO2005011672A1 (en) | Oil processing composition for prevention and improvement of lifestyle-related diseases | |
| JP5547486B2 (en) | Composition containing sesamin and arachidonic acid | |
| JP2005185188A (en) | Composition containing treated product of acerola and l-carnitine | |
| JP2006056836A (en) | Adipose tissue-specific secreted protein production-enhancing composition | |
| JP2007045814A (en) | Cholesterol regulating agent | |
| Karuna et al. | Vegetable oil-based nutraceuticals | |
| JP2007230987A (en) | Anti-obestic agent | |
| JP2011001348A (en) | Formulation for prevention or alleviation of alcohol drunkenness or hangover | |
| JP4191420B2 (en) | Edible oil and fat composition comprising a licorice hydrophobic extract | |
| EP3744323A1 (en) | Composition for preventing or improving nociceptive pain | |
| JP5066856B2 (en) | Adiponectin secretion promoter | |
| US20090041876A1 (en) | Oil/fat-containing composition for suppression of carcinogenesis | |
| JPWO2004064830A1 (en) | Oil processing composition for prevention and improvement of lifestyle-related diseases | |
| JP2008303154A (en) | Body fat accumulation inhibitor | |
| JP2006306855A (en) | Oil and fat-containing composition for suppressing carcinogenesis | |
| JP7356833B2 (en) | Peripheral thermostimulant | |
| JP4997514B2 (en) | Antihypertensive agent | |
| JP2010105948A (en) | Fatty liver inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160524 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160722 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160830 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160916 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6010665 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |